Pharmaceuticals France

France Contraceptive Innovations Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

France Contraceptive Innovations Market Industry Trends and Forecast to 2034: Segmented by (Product, Hormone, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $116.7 Mn Placeholder estimate
Estimate 2025 $122.6 Mn 2.6% of the global market
Projected 2034 $191.8 Mn 56.5% Adds $69.2 Mn over 9 forecast years
CAGR 2025–2034 5.1% Faster than 26% of 180 Pharmaceuticals markets here
Key players 6 +1
  • France is 2.6% of the global market.
  • In Europe, the largest is Germany at $149.5 Mn.
  • Fastest growing: Russia at 6% a year.
  • France ranks 2nd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$69.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Contraceptive Innovations Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $116.7 Mn — —
2025 (base) $122.6 Mn +$5.9 Mn —
2026 (forecast) $128.9 Mn +$6.3 Mn +5.1%
2027 (forecast) $135.4 Mn +$6.6 Mn +10.5%
2028 (forecast) $142.3 Mn +$6.9 Mn +16.1%
2029 (forecast) $149.6 Mn +$7.3 Mn +22%
2030 (forecast) $157.2 Mn +$7.6 Mn +28.2%
2031 (forecast) $165.3 Mn +$8.0 Mn +34.8%
2032 (forecast) $173.7 Mn +$8.4 Mn +41.7%
2033 (forecast) $182.5 Mn +$8.9 Mn +48.9%
2034 (forecast) $191.8 Mn +$9.3 Mn +56.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France Contraceptive Innovations Market Analysis at a glance
Market size, 2025$122.6 Mn placeholder estimate
Forecast, 2034$191.8 Mn placeholder estimate
Growth (CAGR), 2025–20345.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, hormone and end user (see all)
Key playersBayer AG, Organon, Perrigo Company plc, Evofem Biosciences, Mithra Pharmaceuticals and 1 more (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France Contraceptive Innovations Market Analysis Executive Summary

Contraceptive innovations are newer birth-control options such as hormone-free gels, long-acting injectables, vaginal rings and over-the-counter pills.

Key segments of the contraceptive Innovations market include product (Over-the-Counter Pills, Long-Acting Injectables and Vaginal Rings) and hormone (Hormonal and Non-Hormonal).

Bar chart: France Contraceptive Innovations market size, 2024–2034, placeholder estimates. $116.7 Mn in 2024, $122.6 Mn in 2025 and $191.8 Mn in 2034, 5.1% CAGR.
France Contraceptive Innovations market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France Contraceptive Innovations Market Dynamics

Market Growth Drivers

Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the contraceptive Innovations market. New products designed around women's biology and digital care are improving access.

Opportunity

Femtech, personalised care and new treatments for under-served conditions open strong growth for the contraceptive Innovations market, especially as employers and payers add women's health benefits.

Market Restraints

Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the contraceptive Innovations market.

Competitive Landscape for Contraceptive Innovations Market in France

The contraceptive Innovations market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Contraceptive Innovations Market in France

Contraceptive Innovations in France: rules and payment

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for contraceptive Innovations. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Contraceptive Innovations right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Contraceptive Innovations in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 3rd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 6th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Contraceptive Innovations market in France?
Placeholder estimate: about $122.6 Mn in 2025, rising to about $191.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Contraceptive Innovations market in France growing?
Placeholder estimate: about 5.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Contraceptive Innovations market report cover?
The report splits the market by product (Over-the-Counter Pills, Long-Acting Injectables, Vaginal Rings, Non-Hormonal Gels and more), hormone (Hormonal, Non-Hormonal) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Contraceptive Innovations market?
Key players include Bayer AG, Organon, Perrigo Company plc, Evofem Biosciences, Mithra Pharmaceuticals and TherapeuticsMD.
What is driving the Contraceptive Innovations market?
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the contraceptive Innovations market. New products designed around women's biology and digital care are improving access.
Who regulates Contraceptive Innovations in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on contraception and women's health

See the topic